

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PZ003P3

Ruben et al.

Application No.: 09/853,161

Group Art Unit: 1634

Filed: May 11, 2001

Examiner: M. Sheinberg

For: Antibodies to Protein HPMBQ91 (as amended)

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 § CFR 1.56

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references A-Q cited on the attached Form PTO/SB/08A. Copies of references A-Q were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/152,060, filed September 11, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the above-listed file for copies of references A-Q.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Dated: March 14, 2003

Respectfully submitted,

Janet M. Martineau

Registration No.: 46,903


HUMAN GENOME SCIENCES, INC.

Docket No.: PZ003P3

9410 Key West Avenue Rockville, Maryland 20850

(301) 315-2723

KKH/JMM/SA/FR/ba



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known			
INF	ORMATION D	ISCLO	SURE	Application Number	09/853,161		
	TEMENT BY			Filing Date	May 11, 2001		
SIA	TEMENT DI	AFFLI	CAIVI	First Named Inventor	RUBEN, et al.		
				Group Art Unit	1634		
(use as many sheets a	as necessa	ary)	Examiner Name	Sheinberg, M.		
Sheet	1	of	2	Attorney Docket Number	PZ003P3		

	U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No. 1	U.S. Patent Document Kind Code ² Number (if known)		Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
	Α	5,536,637	Kenneth Jacobs	07/16/1996						

				F	DREIGN PATENT DOCUMENT	ΓS		
Examiner Initials	Cite No. 1	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (if known)		Code⁵	01 01100 2 00001110111	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	В	EP	0679 716A		Matsubara et al.	11/02/1995		Ť
	С	WO	97/07198		Genetics Inst. Inc.	02/27/1997		
	D	wo	00/09709		Incyte	02/24/2000		
	Е	wo	98/40483		Human Genome Sciences	09/17/1998		


	OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т6					
	F	Geneseq Accession No: Y12863, DUCLERT et al., "Human 5' EST secreted protein SEQ ID NO:453" (June 21, 1999).						
	G	GenBank Accession No: R60718, HILLIER et al., "yh02c10.r1 Homo sapiens cDNA clone 42116 5" (May 29, 1995).						
	Н	GenBank Accession No: T30875, ADAMS et al., "EST24351 Homo sapiens cDNA 5' end similar to None" (Jan. 11, 1995).	8					
	I	GenBank Accession No: N30539, HILLIER et al., "yx49g02.r1 Homo sapiens cDNA clone 265106 5" (Jan. 6, 1996).						
	J	GenBank Accession No: H28536, HILLIER et al., "y159b11.r1 Homo sapiens cDNA clone 162525 5" (July 19, 1995).						
	K	GenBank Accession No: H22240, HILLIER et al., "y131h11.s1 Homo sapiens cDNA clone 159909 3" (July 8, 1995).						
	L	GenBank Accession No: H56776, DIATCHENKO et al., "EST0040 Testis, Subtracted Homo sapiens cDNA clone LUDA-ST6, mRNA sequence" (Oct. 4, 1995).						

Examiner	Date	
Signature	Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	or form 1449/PTO			Complete if Known		
IN	FORMATION D	ISCLO	SURE	Application Number	09/853,161	
ST	ATEMENT BY	APPI I	CANT	Filing Date	May 11, 2001	
		ALLEN		First Named Inventor	RUBEN, et al.	
				Group Art Unit	1634	
	(use as many sheets	as necessa	iry)	Examiner Name	Sheinberg, M.	
Sheet	2	of	2	Attorney Docket Number	PZ003P3	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т				
	M	GenBank Accession No: AAA72813, HOSTOMSKY et al., "trypsin inhibitor" (April 27, 1993).					
	N	GenBank Accession No: H56777, DIATCHENKO et al., "EST0041 Testis, Subtracted Homo sapiens cDNA clone LUDA-ST2, mRNA sequence" (Oct. 4, 1995).					
	0	BARTON et al., "Protein Structure Prediction, A Practical Approach," IRL Press at Oxford Univ. Press, U.K., pp. 31-63 (1996).					
	P	GEORGE et al., "Current Methods in Sequence Comparison and Analysis," Macromolecular Sequencing & Synthesis-Selected Methods and Applications, D.H. Schlesinger (Ed.) Alan R. Liss, Inc. New York, pp. 127-149 (1988).					
	Q	SUZUKI et al., An Introduction to Genetic Analysis, 3d Ed., W.H. Freeman and Company, New York, pp. 421-423 (1986).	Ī				

Examiner	Date	
	Date	
Signature	Considered	
	Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.